Pittsburgh compound-B and alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study

Dementia and Geriatric Cognitive Disorders

Volumn 29, Issue 3, 2010, Pages 204-212

  Degerman Gunnarsson, M ^a   Lindau, M ^a,f   Wall, A ^c   Blennow, K ^d   Darreh Shori, T ^e   Basu, S ^b   Nordberg, A ^e   Larsson, A ^a   Lannfelt, L ^a   Basun, H ^g   Kilander, L ^a  

^a Department of Public Health/Geriatrics ^*  (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c BIACORE AB   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f STOCKHOLM UNIVERSITY   (Sweden)

^g BioArctic Neuroscience   (Sweden)

Author keywords

A 1 42; A x 42 APOE; Alzheimer's disease; Biomarkers; CSF; Cystatin C; Follow up; PET FDG; Pittsburgh Compound B

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; CYSTATIN C; FLUORODEOXYGLUCOSE F 18; GLUCOSE; MEMANTINE; PITTSBURGH COMPOUND B;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG RETENTION; DRUG URINE LEVEL; FEMALE; FOLLOW UP; GLUCOSE BRAIN LEVEL; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK FACTOR;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANILINE COMPOUNDS; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; BRAIN; COGNITION; DATA INTERPRETATION, STATISTICAL; EDUCATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; RADIOPHARMACEUTICALS; RISK FACTORS; THIAZOLES;

EID: 77949555201     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000281832     Document Type: Article

References (63)

1. Nelson PT, Braak H, Markesbery WR: Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 2009; 68: 1-14.
2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944. (Pubitemid 14076461)
3. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4: DSM-IV. Washington, APA, 1994.
4. Blennow K, Vanmechelen E: CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. Brain Res Bull 2003; 61: 235-242. (Pubitemid 36952469)
5. Hampel H, Mitchell A, Blennow K, Frank RA, Brettschneider S, Weller L: Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm 2004; 111: 247-272. (Pubitemid 38316604)
6. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak- Vance MA, Risch N, van Duijn CM, APOE and Alzheimer Disease Meta Analysis Consortium: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer's disease: a metaanalysis. JAMA 1997; 278: 1349-1356.
7. Klunk WE, Engler H, Nordberg A, Wang Y, Blomquist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Baretta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-319. (Pubitemid 38269583)
8. Ikonomovic MD, Kunk WE, Abrahamson EE, Mathis CA, Price JC, Tsoplas WE, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST: Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131: 1630-1645. (Pubitemid 351806448)
9. Edison P, Rowe CC, Rinne JO, Hg S, Ahmed I, Kemppainen N, Villmage VL, O'Keefe G, Någren K, Chaudhuri R, Master CL, Brooks DJ: Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB-PET. J Neurol Neurosurg Psychiatry 2008; 79: 1331-1338.
10. Villemage VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, Ackermann U, Cowie TF, Currie J, Chan SG, Jones G, Tochon-Danguy H, O'Keefe G, Master CL, Rowe CC: A- deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 2008; 46: 1688-1697.
11. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Långström B, Nordberg A: Two-year follow- up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129: 2856-2866. (Pubitemid 44684508)
12. Scheinin NM, Aalto S, Koikkalainen J, Lötjönen J, Karrasch M, Kemppainen N, Viitanen M, Någren K, Helin S, Scheinin M, Rinne JO: Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 2009; 73: 1186-1192.
13. Forsberg A, Engler H, Almquist O, Blomquist G, Hagman G, Wall A, Ringheim A, Långström B, Nordberg A: PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29: 1456-1465.
14. Grimmer T, Riemenschneider M, Förstl H, Henriksen G, Klunk W, Mathis C, Shiga T, Wester HJ, Kurz A, Drzezga A: Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentrations in cerebrospinal fluid. Biol Psychiatry 2009; 65: 927-939.
15. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A- 42 in humans. Ann Neurol 2006; 59: 512-519.
16. Blum-Degena D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P: Interleukin-1- and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995; 202: 17-20.
17. Cacabelos R, Barquero M, Garcia P, Alvarez XA, Varela de Seijas E: Cerebrospinal fluid interleukin-1- (IL-1- ) in Alzheimer's disease and neurological disorders. Methods Find Exp Clin Pharmacol 1991; 13: 455-458.
18. Garlind A, Brauner A, Höjeberg B, Basun H, Schultzberg M: Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients. Brain Res 1999; 826: 112-116. (Pubitemid 29222965)
19. Andreasen N, Sjögren M, Blennow K: CSF markers for Alzheimer's disease: total tau, phospho-tau and A- 42. World J Biol Psychiatry 2003; 4: 147-155.
20. Frankfort SV, Tulner LR, van Campen JP, Verbeek MM, Jansen RW, Beijnen JH: Amyloid- protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature. Curr Clin Pharmacol 2008; 3: 123-131.
21. Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ: Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem Int 2001; 39: 409-413. (Pubitemid 32907405)
22. Jesse S, Steinacker P, Cepek L, von Arnim CA, Tumani H, Lehnert S, Kretzschmar HA, Baier M, Otto M: Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease. J Alzheimers Dis 2009; 17: 541-551.
23. Sundelöf J, Kilander L, Helmersson J, Larsson A, Rönnemaa E, Degerman Gunnarsson M, Sjögren P, Basun H, Lannfelt L, Basu S: Systemic tocopherols and FS-isoprostanes and the risk of Alzheimer's disease and dementia: a prospective population-based study. J Alzheimers Dis 2009; 18: 71-78.
24. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Bürger K, Hampel H, Frölich L, Wolf S, Prinz B, Jahn H, Luckhaus C, Perneczky R, Hüll M, Schröder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, Kölsch H, Reulbach U, Esselmann H, Maler JM, Bibl M, Kornhuber J, Wiltfang J: Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry DOI:10.1038/2008.84.
25. Riddell D, Zhou H, Atchison K, Warwick H, Atkinson P, Jefferson J, Xu L, Aschmies S, Kirksey Y, Hu Y, Wagner E, Parratt A, Xu J, Li Z, Zaleska M, Jacobsen S, Pangalos M, Reinhart P: Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci 2008; 28: 11445-11453.
26. Sundelöf J, Arnlöv J, Ingelsson E, Sundström J, Basu S, Zethelius B, Larsson A, Irizarry MC, Giedraitis V, Rönnemaa E, Degerman- Gunnarsson M, Hyman BT, Basun H, Kilander L, Lannfelt L: Serum cystatin C and the risk of Alzheimer disease in elderly men. Neurology 2008; 71: 1072-1079.
27. Galasko D, Bennett D, Sano M: An inventory to assess activities of daily living for the clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 1997; 11: S33-S39. (Pubitemid 27303108)
28. Andreasen N, Hesse C, Davidsson P, Wallin A, Minthon L, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K: Cerebrospinal fluid- -amyloid (1-42) in Alzheimer's disease: differences between early- and late-onset al.zheimer disease and stability during the course of disease. Arch Neurol 1999; 56: 673-680.
29. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K: Evaluation of plasma A- 40 and A- 42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 2008 DOI:10.10016/2008.09.006.
30. Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K: Prediction of Alzheimer's disease using the CSF A- 42/A- 40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2007; 23: 316-320.
31. Blennow K, Wallin A, Ågren H, Spenger C, Siegfried J, Vanmechelen E: Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer's disease? Mol Chem Neuropathol 1995; 26: 231-245. (Pubitemid 26002016)
32. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van der Perre B, Sjögren M, Andreasen N, Blennow K: Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000; 285: 49-52. (Pubitemid 30224621)
33. Darreh-Shori T, Modiri N, Blennow K, Baza S, Kamil C, Ahmed H, Andreasen N, Nordberg A: The apolipoprotein E var- 4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. Neurobiol Aging DOI: 10.1016/200907015.
34. Basu S: Radioimmunoassay of 8-iso-prostaglandin F2- : an index for oxidative injury via free radical catalysed lipid peroxidation. Prostaglandins Leukot Essent Fatty Acids 1998; 68: 319-325.
35. Engler H, Lundberg PO, Ekbom K, Nennesmo I, Nilsson A, Bergström M, Tsukada H, Hartvig P, Långström B: Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease. Eur J Nucl Med Mol Imaging 2003; 30: 186. (Pubitemid 36692897)
36. Andersson JL, Thurfjell L: Implementation and validation of a fully automatic system for intra- and interindividual registration of PET brain scans. J Comput Assist Tomogr 1997; 21: 136-144. (Pubitemid 27061172)
37. Engler H, Lundberg PO, Ekbom K, Nennesmo I, Nilsson A, Bergström M, Tsukada H, Hartvig P, Långström B: Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease. Eur J Nucl Med Mol Imaging 2003; 30: 85-95. (Pubitemid 36692897)
38. Patlak CS, Blasberg RG, Fenstermacher JD: Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3: 1-7.
39. Benton AL, Hamsher K de S: Multilingual Aphasia Examination. Iowa City, University of Iowa, 1976.
40. Wechsler D: WAIS-III. Swedish Version Manual. Stockholm, Harcourt Assessment, 2003.
41. Christensen AL: Luria's Neuropsychological Investigation, ed 2, rev. Risskov, Munksgaard, 1984.
42. Lezak MD, Howieson DB, Loring DW: Neuropsychological Assessment, ed 4. New York, Oxford University Press, 2004.
43. Reitan RM, Wolfson D: The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tucson, Neuropsychology Press, 1993.
44. Claeson LE, Esbjörnsson E, Tännérus BM, Wahlbin M: Claeson-Dahls test för inlärning och minne, rev. Halmstad, The Halmstad Printer, 2003.
45. Bergman I, Blomberg M, Almkvist O: The importance of impaired health and age in normal cognitive aging. Scand J Psychol 2007; 48: 115-125.
46. Koivunen J, Pirttilä T, Kemppainen N, Aalto S, Herukka SK, Jauhianen AM, Hänninen T, Hallikainen M, Någren K, Rinne JO, Soininen H: PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid- -amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008; 26: 378-383.
47. Fagan AM, Roe C, Xiong C, Mintun M, Morris J, Holtzman D: Cerebrospinal fluid tau/- - amyloid 42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64: 343-349.
48. Koopman K, Bastard N, Martin J-J, Nagels G, De Deyn P, Engelborghs S: Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementia using CSF P-tau 181. Neurochem Int 2009; 55: 214-218.
49. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T: Cerebrospinal fluid- -amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009; 66: 382-389.
50. Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, Martin JJ, Vanmechelen E, De Deyn PP: Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 2008; 29: 1143-1159. (Pubitemid 351822410)
51. Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, Galasko D, Hampel H, Hartmann T, Kapaki E, Lannfelt L, Mehta PD, Parnetti L, Petzold A, Pirttila T, Saleh L, Skinningsrud A, Swieten JC, Verbeek MM, Wiltfang J, Younkin S, Scheltens P, Blankenstein MA: A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem 2009; 46: 235-240.
52. Sämgård K, Zetterberg H, Blennow K, Hansson O, Minthon L, Londos E: Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. Int J Geriatr Psychiatry DOI: 10/1002/2353.
53. Schönknecht P, Pantel J, Kaiser E, Thomann P, Schröder J: Increased tau protein differentiates mild cognitive impairment from geriatric depression and predicts conversion to dementia. Neurosci Lett 2007; 416: 39-42. (Pubitemid 46428014)
54. Corder EH, Saunders AM, Stritmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose apolipoprotein E type 4 allele and risk of Alzheimer's disease in late-onset families. Science 1993; 26: 921-923
55. Mayeux R, Saunders A, Shea S, Mirra S, Evans D, Roses A, Hyman B, Crain B, Tang M-X, Phelps C: Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N Eng J Med 1998; 19: 506-511. (Pubitemid 28103134)
56. Drzezga A, Grimmer T, Henriksen G, Muhlau M, Perneczky R, Miederer I, Praus C, Sorg C, Wohlschläger A, Riemenschneider M, Wester HJ, Foersti H, Schwaiger M, Kurz A: Effect of APOE geneotype on amyloid plaque load and gray matter volume in Alzheimer's disease. Neurology 2009; 72: 1487-1494.
57. Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO: PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007; 68: 1603-1606. (Pubitemid 46717985)
58. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk We, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ: Fibrillar amyloid-- burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2009; 106: 6820-6825.
59. Levy E, Sastre M, Kumar A, et al.: Code position of cystatin C with amyloid-- protein in the brain of Alzheimer disease patients. J Neuropathol Exp Neurol 2001; 60: 94-104.
60. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M, Consortium on DLB: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872. (Pubitemid 43970103)
61. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, Mathis CA, Elmaleh DR, Shoup T, Fischman AJ, Hyman BT, Grow JH, Johnson KA: Imaging amyloid deposition in Lewy body diseases. Neurology 2008; 71: 903-910.
62. Merdes AR, Hansen LA, Jeste DV, Galasko D, Hofstetter CR, Ho GJ, Thal LJ, Corey- Bloom J: Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003; 60: 1586-1590. (Pubitemid 36618082)
63. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ, Work Group on Frontotemporal Dementia and Pick's Disease: Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 2001; 58: 1803-1809.